View
4
Download
0
Category
Preview:
Citation preview
2020
~ CONFIDENTIAL ~
• Project leader, Center for
Clinical Immunology
• Senior scientist at XTL
Biopharmaceutical
Gadi Levin, CPA, MBACFO and Director
• CFO, LabStyle Innovations Ltd
• CFO, BriaCell Therapeutics Corp.
• VP / CFO of 2 investment houses
David Goren, MBACEO and Chairman
• Head, Pfizer Worldwide
Strategy and BD
• CEO, Pfizer Israel
• President, AstraZeneca Israel
• VP Digital Health Strategy,
AstraZeneca
Mordechai Applebaum, PhD, MA
R&D Director• Senior scientist and PM, Enlivex
Therapeutics
• US Grant Consultant, FreeMind
Riva Kovjazin, MD, PhDSenior Scientist
~ CONFIDENTIAL ~
Ari S. Kellen, MD, MBADirector
• Senior partner, McKinsey & Co.
• EVP and GM, Bausch & Lomb US
• Advisory board, BioNanoSim
(BNS)
Shawn Langer, MDDirector
• Senior partner, McKinsey & Co.
• Portfolio manager, BHMS
Investments
~ CONFIDENTIAL ~
Targeting COVID-19 (infectious disease) andsolid tumors
Clinical stage immunotherapy
VaxHit™ target ID forsignal peptides and mAbs
5 Patent families
VXL traded on TSXV (2016)
Successful Phase 1/2a multiple myeloma clinical trial
Orphan designation for multiple myeloma (FDA / EMA)
05
06
07
01
02
03
04 08 P-ESBP In-licensing
~ CONFIDENTIAL ~
1Antigen specific multiple epitope
vaccines
2Recombinant
Abs + companion
diagnostic for ImMucin™
3Antigen specific multiple
epitope anti-infectives
4P-ESBP (BGU) 5COVID-19
(pending)
~ CONFIDENTIAL ~
Diagnostics Efficacy Prophylaxis Treatment
Oncology
Infectious Disease (COVID-19)
~ CONFIDENTIAL ~
Antigen Mining
VaxHit™ Proprietary Algorithm
Immune validation
Preclinical development
Clinical
MUC1-SP
Additional SPs
Tuberculosis
Other candidates
P-ESBP
mAb program
On
colo
gyID
COVID-19 Vaccine
~ CONFIDENTIAL ~Adapted from Kovjazin and Carmon, 2014
~ CONFIDENTIAL ~
HLA class I HLA class II
2
4
5
Adapted from Kovjazin and Carmon, 2014
1
Robust immune response(cellular and humoral)
2
3
HLA-independent exposure(circumventing tumor immune escape)
4
TAP-independent HLA loading(circumventing tumor immune escape)
5
Wide HLA subclass restriction(applicable to heterogenous population)
Densely populated with antigens(multi-antigen vaccine)
31
~ CONFIDENTIAL ~
MUC1-SP (oncology) TB SP (infectious disease)
Adapted from Kovjazin et al (2011, Vaccine) Adapted from Kovjazin et al (2013, Clinical Vaccine Immunology)
PPD – purified protein derivativeTT – tetanus toxoid
~ CONFIDENTIAL ~
MUC1-SP (oncology) TB SP (infectious disease, VXL-211)
Kovjazin et al (2011, Vaccine) Adapted from Kovjazin et al (2013, Clinical Vaccine Immunology)
~ CONFIDENTIAL ~
Feb - March 2020:• Innovative candidate identified using proprietary VaxHit™ tool
with potential activity against COVID-19 (alone or in combination)
•Preclinical (non-GMP) production completed
•Preclinical efficacy experiments designed and begun
~ CONFIDENTIAL ~
• Secure partnership for COVID-19 infected blood samples and experiments (including recovered patients); initiate experiments on these samples
• Secure regulatory pathway, necessary data to clinical trial
• Initiate GMP production
• Explore additional funding options
Recommended